Zoetis Inc. Files 8-K: Material Agreement, Equity Sales

Ticker: ZTS · Form: 8-K · Filed: 2025-12-18T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, equity-sale, regulation-fd

TL;DR

Zoetis signed a big deal & sold some stock. Details in new 8-K.

AI Summary

On December 15, 2025, Zoetis Inc. entered into a material definitive agreement, potentially involving a direct financial obligation or an off-balance sheet arrangement. The company also reported unregistered sales of equity securities and made a Regulation FD disclosure. This filing was made on December 18, 2025.

Why It Matters

This 8-K filing indicates significant corporate activity for Zoetis Inc., including a new material agreement and equity transactions, which could impact its financial structure and shareholder value.

Risk Assessment

Risk Level: medium — The filing mentions a material definitive agreement and unregistered sales of equity, which can introduce financial obligations and potential dilution, warranting a medium risk assessment.

Key Players & Entities

FAQ

What type of material definitive agreement did Zoetis Inc. enter into?

The filing indicates Zoetis Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in this summary.

What was the nature of the unregistered sales of equity securities?

The filing states there were unregistered sales of equity securities, but the specifics of these sales, including the amount and terms, are not detailed here.

What is the significance of the Regulation FD Disclosure?

A Regulation FD Disclosure is made when a company intentionally or unintentionally discloses material non-public information to securities market professionals or investors.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on December 15, 2025.

What is Zoetis Inc.'s principal executive office address?

Zoetis Inc.'s principal executive office is located at 10 Sylvan Way, Parsippany, New Jersey 07054.

From the Filing

0001193125-25-324853.txt : 20251218 0001193125-25-324853.hdr.sgml : 20251218 20251218161738 ACCESSION NUMBER: 0001193125-25-324853 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20251215 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251218 DATE AS OF CHANGE: 20251218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 251583307 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 8-K 1 d35588d8k.htm 8-K 8-K false 0001555280 0001555280 2025-12-15 2025-12-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 15, 2025     Zoetis Inc. (Exact name of registrant as specified in its charter)       Delaware   001-35797   46-0696167 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   10 Sylvan Way , Parsippany , New Jersey   07054 (Address of principal executive offices)   (Zip Code) (973) 822-7000 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.01 per share   ZTS   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01 Entry into a Material Agreement. Indenture and Notes On December 18, 2025, Zoetis Inc., a Delaware corporation (“Zoetis” or the “Company”), completed its previously announced private offering (the “Offering”) of 0.25% Convertible Senior Notes due 2029 (the “Notes”). The Notes were sold in a private placement under a purchase agreement, dated as of December 15, 2025 (the “Purchase Agreement

View on Read The Filing